Web
Analytics
The news is by your side.

drug

Roche lung cancer drug success adds to pressure on Bristol

COPENHAGEN: Lung cancer patients on Roche's immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb's dominant position in the field. The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even in people with low or no levels of a protein called PD-L1, which is often used to test suitability for immunotherapy. The study results were presented at the annual European…

Novartis study shows skin cancer combo also works on lungs

CHICAGO: A Novartis trial of two drugs against an aggressive lung cancer bodes well for broadening their use beyond melanoma, the Swiss drugmaker told the American Society of Clinical Oncology's conference in Chicago on Tuesday. Novartis's Tafinlar and Mekinist combination shrank tumors in 63 percent of the trial's 57 people with BRAF V600E-mutation positive non-small cell lung cancer who had failed on chemotherapy, the company said, citing a Phase II study.